Form 4: Dianthus Director Exercises, Sells Shares Under 10b5-1 Plan

Dianthus Therapeutics Director Paula Soteropoulos exercised stock options and sold the resulting common shares under a pre-arranged trading plan.

Summary

• Paula Soteropoulos, a Director of Dianthus Therapeutics, Inc. (DNTH), reported a transaction on March 31, 2026.
• The transaction involved the exercise of 599 stock options at an exercise price of $8.44 per share.
• Immediately following the exercise, 599 shares of common stock were sold at a price of $80.11 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Soteropoulos on December 23, 2025.
• Following these transactions, Ms. Soteropoulos beneficially owns 0 shares of common stock and 0 derivative securities related to the exercised options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral. While a director selling shares might typically be seen negatively, the pre-arranged 10b5-1 plan mitigates concerns about immediate insider sentiment, indicating a planned liquidity event rather than a reaction to new company developments.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled and transparent sale not based on immediate insider information.
• The director realized a significant profit from the exercise of options and subsequent sale of shares.

Negatives

• A director reduced their direct ownership in the company by selling shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are routinely monitored by investors for insights into management's perception of future company performance. However, transactions executed under Rule 10b5-1 plans are pre-scheduled and generally considered less indicative of immediate insider sentiment compared to discretionary sales, as they are set up in advance to avoid accusations of trading on material non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact due to the small number of shares involved and the pre-planned nature of the transaction.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider transaction (exercise and sell) by a director. The small number of shares involved and the existence of a 10b5-1 plan suggest it is not indicative of a significant change in company fundamentals or management's outlook, thus not warranting a change in investment stance based solely on this filing.

Keywords

Dianthus Therapeutics, DNTH, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1, Director Transaction, Paula Soteropoulos